NARDIL (phenelzine sulfate) by Pfizer is clinical pharmacology monoamine oxidase is a complex enzyme system, widely distributed throughout the body. First approved in 1961.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
NARDIL (phenelzine sulfate) is a monoamine oxidase inhibitor (MAOI) oral tablet approved in 1961 for depression. It works by inhibiting monoamine oxidase, a complex enzyme system that regulates neurotransmitter levels including serotonin, norepinephrine, and dopamine. The drug is indicated for patients with major depressive disorder, particularly those who have not responded to other antidepressants.
Mature product with minimal Medicare claims and declining uptake; commercial team likely focused on retention and specialty care partnerships rather than growth expansion.
CLINICAL PHARMACOLOGY Monoamine oxidase is a complex enzyme system, widely distributed throughout the body. Drugs that inhibit monoamine oxidase in the laboratory are associated with a number of clinical effects. Thus, it is unknown whether MAO inhibition per se, other pharmacologic actions, or an…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Worked on NARDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NARDIL offers expertise in complex pharmacology, safety risk management, and psychiatry specialist marketing, but limited career growth visibility given the LOE-approaching lifecycle and minimal Medicare claim volume (278 claims, 2023). Positions are typically sustaining roles focused on maintaining prescriber relationships, managing safety communications, and optimizing formulary position.